M&A in the Healthcare Industry: Trends and Regulatory Challenges
M&A in the healthcare industry worldwide has been displaying significant growth all through the latter half of 2023. Mergers and acquisitions have proved to be a valuable metamorphic tool that can alter the landscape of the health and pharmaceutical industry. Results of a survey conducted revealed that 68% of the top executives in the sector anticipate a rise in the volume of deals. At least 60% believe that M&A transactions in healthcare will dominate instead of private equity sales and IPOs.
M&A in the healthcare industry worldwide has been displaying significant growth all through the latter half of 2023. Mergers and acquisitions have proved to be a valuable metamorphic tool that can alter the landscape of the health and pharmaceutical industry.
Results of a survey conducted revealed that 68% of the top executives in the sector anticipate a rise in the volume of deals. At least 60% believe that M&A transactions in healthcare will dominate instead of private equity sales and IPOs.
This sector is evolving rapidly, and companies are focusing on vertical mergers and developing digital capabilities. Building on and scaling the healthcare ecosystem has fuelled accelerated growth as the industry navigates post-COVID challenges.
Pharmaceuticals and life sciences (PLS) and healthcare services (HCS) are attracting investors as they restructure their vision and strategies. They are also reorganizing their assets and capabilities with the objective of long-term sustainability and growth.
*FREE DOWNLOAD*
The Ultimate Guide To Pitch Decks
Trends in the M&A in the Healthcare Industry
Large-cap pharmaceutical companies are keen on acquiring and investing in mid-size and small biotech startups and businesses. The objective here is to fill gaps in the pipeline for sourcing supplies and innovations, including Intellectual Property and technology.
At the same time, M&A in the healthcare industry is not without challenges. The adverse economic conditions and rising interest rates are affecting acquirers’ ability to raise adequate capital to buy companies. Even so, sellers prefer to sell their startups as an exit strategy instead of IPOs.
Further, publicly traded companies with underperforming stock prices are converting into private ownership. Cash-rich private equity firms are quickly snapping them up.
Larger M&A deals can undoubtedly unlock substantial value, but they also carry higher risk. That is, in cases where the targeted company values more than 30% of the acquirer’s size. The core areas where M&A transactions occur include technology and ancillary services like diagnostics and supportive. Cost reduction and improving the quality of care are also objectives.
Studies indicate that M&As have a higher probability of creating value and achieving complete integration in two years post-closing. As against five years after the closing. To make that happen, companies now approach the merger with a disciplined and carefully-strategized process.
Continue reading the full guide
Related guides
Read on Startup Fundraising ·
More articles ·
Browse the Library
